Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells

Journal of Cellular Biochemistry

Volumn 108, Issue 5, 2009, Pages 1203-1210

  Limor, Rona ^a   Kaplan, Marielle ^b   Sharon, Orly ^a   Knoll, Esther ^a   Naidich, Michal ^a   Weisinger, Gary ^a   Keidar, Shlomo ^b   Stern, Naftali ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

12 Lipoxygenase; 15 Lipoxygenase; Aldosterone; LDL oxidation; vascular smooth muscle cell

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 12 HYDROXYICOSATETRAENOIC ACID; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALDOSTERONE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPLERENONE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SPIRONOLACTONE;

ARTICLE; ATHEROGENESIS; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPID OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ALDOSTERONE; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; CELL LINE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LIPOPROTEINS, LDL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDATION-REDUCTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, MINERALOCORTICOID; UP-REGULATION;

EID: 72449191387     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22352     Document Type: Article

References (51)

1. Aviram M, Vaya J. 2001. Markers for LDL oxidation. Methods Enzymol 335:244-256.
2. Belkner J, Stender H, Kuhn H. 1998. The rabbit 15 lipoxygenase preferentially oxygenates LDL cholesterol esters and this reaction does not require vitamin E. J Biol Chem 273:23225-23232. (Pubitemid 28417507)
3. Brilla CG, Matsubara S, Weber KT. 1993. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosterism. J Mol Cell Cardiol 25:563-575. (Pubitemid 23208145)
4. Caprio M, Newfell BG, La Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. 2008. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102:1359-1367.
5. Chang WC. 2003. Cell signaling and gene regulation of human 12(S)-lipoxygenase expression. Prostaglandins Other Lipid Mediat 71:277-285. (Pubitemid 36929796)
6. Cyrus T, Witztum J, Rader D, Tangirala R, Fazio S, Linton MF, Funk CD. 1999. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo-E-deficient mice. J Clin Invest 103:1597-1604.
7. Eskra JD, Pereira MJ, Ernes MJ. 1986. Solid-phase extraction and high-performance liquid chromatography analysis of lipoxygenase pathway products. Anal Biochem 154:323-337.
8. Farman N, Rafestin-Oblin ME. 2001. Multiple aspects of mineralocorticoid selectivity. Am J Physiol (Renal Physiol) 280:F181-F192.
9. Fritsh Neves M, Schiffrin EL. 2003. Aldosterone: A risk factor for vascular disease. Curr Hypertens Rep 5:59-65. (Pubitemid 38898933)
10. Funder JW. 1997. Glucocorticoid and mineralocorticoid receptors: Biology and clinical relevance. Annu Rev Med 48:231-240.
11. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. 2002. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am J Physiol (Renal Physiol.) 282:F669-F679. (Pubitemid 34654514)
12. Grossmann C, Gekle M. 2007. Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors? Mol Cell Endocrinol 277:6-12.
13. Grossmann A, Benesic AW, Krug R, Freudinger S, Mildenberger B, Gassner M, Gekle M. 2005. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 19:1697-1710. (Pubitemid 41007884)
14. Hatakeymana H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. 1994. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth cells. J Biol Chem 269:24316-24320. (Pubitemid 24300976)
15. Hollenberg NK. 2004. Aldosterone in the development and progression of renal injury. Kidney Int 66:1-9. (Pubitemid 38870076)
16. Isenovi ER, Jacobs DB, Kedees MH, Sha Q, Milivojevic N, Kawakami K, Gick G, Sowers JR. 2004. Angiotensin II regulation of the Na+ pump involves the phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways in vascular smooth muscle cells. Endocrinology 145:1151-1160. (Pubitemid 38280995)
17. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. 2000. Mechanical stretch stimulates growth of vascular smooth muscle cells via epidermal growth factor receptor. Am J Physiol (Heart Circ Physiol) 278:H521-H529. (Pubitemid 30131253)
18. Jaffe I, Mendelsohn M. 2005. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 96:643-649. (Pubitemid 40478331)
19. Kisch ES, Jaffe A, Knoll E, Stern N. 1997. Role of the lipoxygenase pathway in angiotensin II-induced vasoconstriction in the human placenta. Hypertension 29:796-801. (Pubitemid 27097987)
20. Krug AM, Grossmann C, Schuster C, Freudinger R, Mildenberger S, Govindan MV, Gekle M. 2003. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 278:43060-43066. (Pubitemid 37345921)
21. Kuhn H, Chan L. 1997. The role of 15-lipoxygenase in atherogenesis: Pro and antiatherogenic action. Curr Opin Lipidol 8:111-117. (Pubitemid 27235071)
22. Kuhn H, Heydeck D, Hugou I, Gniwotta C. 1997. In vivo action of 15-Lipoxygenase in early stages of human atherogenesis. J Clin Invest 99:888-893.
23. Lifton RP, Gharav AG, Geller DS. 2001. Molecular mechanism of human hypertension. Cell 104:545-556.
24. Limor R, Weisinger G, Gilad S, Knoll E, Sharon O, Jaffe A, Kohen F, Berger E, Lifshizt-Mercer B, Stern N. 2001. A novel form of platelet-type 12-lipoxygenase mRNA in human vascular smooth muscle cells. Hypertension 38:864-871. (Pubitemid 34258684)
25. Limor R, Kaplan M, Sawamura T, Sharon O, Keidar S, Weisinger G, Knoll E, Naidich M, Stern N. 2005. Angiotensin II increases the expression of lectin-like oxidized low-density lipoprotein receptor-1 in human vascular smooth muscle cells via a lipoxygenase-dependent pathway. Am J Hypertens 18:299-307. (Pubitemid 40409908)
26. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. 2003. Aldosterone regulates vascular reactivity: Short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108:2400-2406. (Pubitemid 37413549)
27. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. 2004. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109:2792-2800. (Pubitemid 38737927)
28. Mnegold JC, Falkenstein E, Wehling M, Chris M. 1999. Rapid aldosterone effects on thyrosine phosphorylation in vascular smooth muscle cells. Cell Mol Biol (Noisy-le-grands) 45:805-813.
29. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. 2001. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481-488. (Pubitemid 32323377)
30. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. 2004. The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 45:993-1007. (Pubitemid 38679495)
31. Nishio E, Watanabe Y. 1997. The regulation of mitogenesis and apoptosis in response to the persistent stimulation of alpha1-adrenoceptors: A possible role of 15-lipoxygenase. Br J Pharmacol 122:1516-1522. (Pubitemid 27503947)
32. Noguchi N, Yamashita H, Hamahara J, Nakamura A, Kuhn H, Niki E. 2002. The specificity of lipoxygenase-catalyzed lipid peroxidation and the effects of radical-scavenging antioxidants. Biol Chem 383:619-626. (Pubitemid 34506299)
33. Ohta S, Nishihara J, Oka Y, Todo H, Kumon Y, Sakaki S. 1995. Possible mechanism to induce protein kinase C-dependent arterial smooth muscle contraction after subarachnoid haemorrhage. Acta Neurochir (Wien) 137:217-225. (Pubitemid 26002590)
34. Parmentier JH, Muthalif MM, Saeed AE, Malik KU. 2001. Phospholipase D activation by norepinephrine is mediated by 12(s)-, 15(s)-, and 20-hydroxyeicosatetraenoic acids generated by stimulation of cytosolic phospholipase A 2 tyrosine phosphorylation of phospholipase D2 in response to norepinephrine. J Biol Chem 276:15704-15711. (Pubitemid 37391597)
35. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. 2003a. Effects of eplerenone, enalapril, and eplerenone / enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 108:1831-1838. (Pubitemid 37296092)
36. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717.
37. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. 2003b. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 348:1309-1321.
38. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. 2002. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802-H1810. (Pubitemid 35217013)
39. Rossol-Haseroth K, Zhou Q, Braun B, Boldyreff B, Falkenstein E, Wehling M, Losel RM. 2004. Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone. Biochem Biophys Res Commun 318:281-288. (Pubitemid 38526277)
40. Saito F, Hori MT, Berger M, Chang CT, Golub M, Stern N, Tuck ML. 1992. 12-Lipoxygenase products modulate calcium signals in vascular smooth muscle cells. Hypertension 20:138-143.
41. Steinberg D, Parthasarathy S, Carew TE, Witztum JL. 1989. Beyond cholesterol: Modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924. (Pubitemid 19101597)
42. Stern N, Golub M, Nozawa K, Berger M, Knoll E, Yanagawa N, Natarajan R, Nadler JL, Tuck ML. 1989. Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade. Am J Physiol 257:H434-H443.
43. Stern N, Yanagawa N, Saito F, Hori M, Natarajan R, Nadler J, Tuck M. 1993. Potential role of 12-hydroxyeicosatetraenoid acid in angiotensin II-induced calcium signal in rat glomerulosa cells. Endocrinology 133:843-847. (Pubitemid 23238901)
44. Sultana C, Shen Y, Rattan V, Kalra VK. 1996. Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation. J Cell Physiol 167:477-487. (Pubitemid 26168224)
45. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. 1990. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82:1730-1736. (Pubitemid 20367976)
46. Thollon C, Iliou JP, Cambarrat C, Robin F, Vilaine JP. 1995. Nature of the cardiomyocyte injury induced by lipid hydroperoxides. Cardiovasc Res 30:648-655.
47. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. 2004. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 305:33-41. (Pubitemid 38857245)
48. Wen Y, Nadler JL, Gonzales N, Scott S, Clauser E, Natarajan R. 1996. Mechanisms of ANG II-induced mitogenic responses: Role of 12-lipoxygenase and biphasic MAP kinase. Am J Physiol 271(4 Pt 1):C1212-C1220. (Pubitemid 126757719)
49. Wen Y, Gu J, Knaus UG, Thomas L, Gonzales N, Nadler JL. 2000. Evidence that 12-lipoxygenase product 12-hydroxyeicosatetraenoic acid activates p21-activated kinase. Biochem J 349:481-487. (Pubitemid 30465783)
50. Xu W, Takahashi Y, Sakashita T, Iwasaki T, Hattori H, Yoshimoto T. 2001. Low density lipoprotein receptor-related protein is required for macrophage-mediated oxidation of low density lipoprotein by 12/15-lipoxygenase. J Biol Chem 276:36454-36459. (Pubitemid 37384255)
51. Yamashita H, Nakamur A, Noguch N, Ni E, Kuhn H. 1999. Oxidation of low density lipoprotein and plasma by 15-lipoxygenase and free radicals. FEBS Lett 445:287-290. (Pubitemid 29117229)